Drugs / MYL-1401A
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02714322 | Jun 2015 → May 2016 | psoriasis, psoriatic arthritis | Mylan Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MYL-1401A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02714322 ↗ |
| Known as | Adalimumab | “MYL-1401A (Adalimumab)” NCT02714322 ↗ |
| Modality | Protein / enzyme biologic | “Biological: MYL-1401A (Adalimumab)” NCT02714322 ↗ |